L3VLUP
ProSign in

KOD in the 13F filings

Kodiak Sciences Inc · CUSIP 50015M109

Sector · Pharmaceuticals and biotechnologyTheme · Biological productsTheme · Healthcare: biopharma and medtech· L3VLUP-defined
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q1 2024Q4 2023Q1 2023Q4 2022
Quarter end
31 Mar 2023
the date the book describes
Filed
15 May 2023
latest of these filings; the earliest 11 May 2023
Managers listing it
2
at least, of 95 tracked, among listed positions
Comparable managers
93
filed both Q4 2022 and Q1 2023; 2 listed it in both
Shares listed
747,835
combined, among listed positions
Reported value
$4.6m
combined, at the quarter end

Managers listing KOD in Q1 2023

Share of 13F value is the position’s reported value over everything the manager reported that quarter. The share change is against Q4 2022, and only where both filings list the position. A rise in value with no rise in shares is the price, not buying.

2 of 2 holders

ActionFiling
Acadian Asset Management LLC701,622$4.3munder 0.1%Trimmed-29,20311 May 2023 (the filing on sec.gov)
Caxton Associates LLP46,213$287kunder 0.1%Trimmed-42,83415 May 2023 (the filing on sec.gov)

Largest increases and reductions, by shares

Q4 2022 to Q1 2023, among managers that listed it in both quarters or opened it.

Increases

No increase among listed positions.

Reductions

New positions and exits

At least these many: a manager is shown exiting only where its own filing shows the position gone.

New (0)

No new position among listed positions.

Exited (0)

No exit shown by a manager’s own filing.

Ownership over time

Every quarter on file. A quarter-end value moves with the price as well as with the shares held; buyers and sellers count comparable managers, by shares.
1 in Q3 2024 to 3 in Q2 2026

Tracked managers listing it, at least.

012342020202120222023202420252026
the quarter shown share split complete books; unmarked quarters rest on listed positionsClick a quarter to open it.
KOD by quarter
QuarterHoldersReported valueBuyersSellers
Q3 20191$1.6mn.a.n.a.
Q4 20193$535mn.a.n.a.
Q1 20203$368mn.a.n.a.
Q2 20203$447mn.a.n.a.
Q3 20202$473mn.a.n.a.
Q4 20203$1.6bnn.a.n.a.
Q1 20213$1.3bnn.a.n.a.
Q2 20214$1.3bnn.a.n.a.
Q3 20213$1.4bnn.a.n.a.
Q4 20213$1.2bnn.a.n.a.
Q1 20222$3.7mn.a.n.a.
Q2 20223$7.0mn.a.n.a.
Q3 20223$5.8mn.a.n.a.
Q4 20223$6.3mn.a.n.a.
Q1 20232$4.6mn.a.n.a.
Q4 20231$5.8m10
Q1 20242$12m11
Q3 20241$5.1m01
Q4 20241$15m01
Q1 20251$5.5m10
Q2 20251$7.3m10
Q3 20253$63m21
Q4 20254$105m1011
Q1 20263$78m1311
Q2 20263$99m1413

Compare with…

Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.

KOD and GILD →KOD and AMGN →KOD and ARGX →Choose a stock to compare with KOD →

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.

Which funds own KOD, latest filings →Back to the 13F Explorer →